Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
499.20M | 500.89M | 503.88M | 488.40M | 488.10M | 434.39M | Gross Profit |
221.43M | 223.20M | 221.99M | 215.47M | 222.69M | 217.83M | EBIT |
17.61M | 19.91M | 28.17M | 151.88M | 40.34M | 59.84M | EBITDA |
46.82M | 60.68M | 66.58M | 66.37M | 80.83M | 92.43M | Net Income Common Stockholders |
14.92M | 16.59M | 17.22M | -103.46M | 33.37M | 50.87M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
109.68M | 103.09M | 102.80M | 80.13M | 77.51M | 161.69M | Total Assets |
769.80M | 743.51M | 772.35M | 802.17M | 928.58M | 744.20M | Total Debt |
4.96M | 3.52M | 5.48M | 21.35M | 7.44M | 13.33M | Net Debt |
-87.85M | -85.56M | -78.31M | -35.20M | -58.48M | -114.27M | Total Liabilities |
82.49M | 73.36M | 77.06M | 104.52M | 100.09M | 99.85M | Stockholders Equity |
687.31M | 670.15M | 695.29M | 697.65M | 828.49M | 644.36M |
Cash Flow | Free Cash Flow | ||||
76.63M | 68.66M | 45.16M | 40.39M | 21.03M | 59.96M | Operating Cash Flow |
74.87M | 77.83M | 73.27M | 62.08M | 55.24M | 106.97M | Investing Cash Flow |
-20.91M | -13.58M | -4.55M | -43.09M | -94.66M | -95.47M | Financing Cash Flow |
-63.86M | -58.55M | -41.86M | -27.92M | -22.20M | -10.73M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | $696.88M | 31.13 | 6.61% | 0.33% | -0.33% | -7.06% | |
73 Outperform | $911.37M | 64.22 | 2.22% | ― | -1.32% | -21.84% | |
70 Outperform | $306.92M | 13.89 | 9.40% | ― | -8.42% | 164.82% | |
67 Neutral | $390.97M | 12.09 | 9.13% | ― | 8.06% | 38.46% | |
66 Neutral | $4.51B | 12.29 | 5.40% | 248.53% | 4.14% | -12.41% | |
59 Neutral | $704.77M | 37.86 | -0.78% | 3.43% | -9.04% | -108.47% | |
59 Neutral | $1.42B | ― | 8.26% | 2.38% | -5.74% | -192.12% |
On May 20, 2025, Robert Bodor stepped down as President and CEO of Proto Labs, Inc., and subsequently entered into a consulting agreement with the company to assist in management transition. The agreement, which includes a monthly fee and provisions for stock options, was extended on May 28, 2025, to continue through November 11, 2025, allowing Dr. Bodor to provide transitional consulting services.
The most recent analyst rating on (PRLB) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on Proto Labs stock, see the PRLB Stock Forecast page.
On May 21, 2025, Proto Labs announced the appointment of Suresh Krishna as the new President and CEO, effective May 20, 2025, succeeding Robert Bodor. With a strong background in driving growth and innovation, Krishna is expected to enhance Proto Labs’ market position and accelerate its production expansion initiatives. The company also reaffirmed its second-quarter 2025 financial outlook, projecting revenue between $124 million and $132 million, and highlighted its ongoing commitment to customer-centric innovation and operational excellence.
The most recent analyst rating on (PRLB) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on Proto Labs stock, see the PRLB Stock Forecast page.